A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Uy, Geoffrey L., Mandrekar, Sumithra J., Laumann, Kristina, Marcucci, Guido, Zhao, Weiqiang, Levis, Mark J., Klepin, Heidi D., Baer, Maria R., Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J., Stock, Wendy, Sanford, Ben, Blum, William G., Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2017
Ämnen:
Myeloid Neoplasia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637402/
https://ncbi.nlm.nih.gov/pubmed/29034366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003053
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk